Qiagen Continues Building PCR-Based Molecular Dx Menu with Johns Hopkins, Celera Deals

Qiagen obtained a worldwide exclusive license from Johns Hopkins University to develop real-time and endpoint PCR companion diagnostic assays based on the PI3K biomarker; and inked a deal to distribute Celera's multiplex PCR-based assay for detecting respiratory pathogens.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.